Mark Laughlin

3.2k citations

33 papers · 2.4k indexed · h-index 18

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 1%
- Antifungal resistance and susceptibility
- HIV/AIDS drug development and treatment

Papers in ⓘ

Infectious Diseases 13
- Antifungal resistance and susceptibility 7
- HIV/AIDS Research and Interventions 5
Virology 10
- HIV Research and Treatment 10

Co-authors: Josephine Lim (6 shared papers)Rachel Courtney (4 shared papers)Francisco González‐Scarano (7 shared papers)Janet M. Harouse (5 shared papers)David Wexler (3 shared papers)Elaine Radwanski (2 shared papers)Steven L. Spitalnik (1 shared paper)Donald H. Silberberg (1 shared paper)
Journals: Alzheimer s & Dementia (5 papers)Clinical Pharmacology & Therapeutics (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Proceedings of the National Academy of Sciences (2 papers)Annals of Neurology (1 paper)
Partner nations: United States Germany Canada

In The Last Decade

Mark Laughlin

33 papers receiving 2.4k citations

Peers

Countries citing papers authored by Mark Laughlin

Since Specialization

Citations

This map shows the geographic impact of Mark Laughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Laughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Laughlin more than expected).

Fields of papers citing papers by Mark Laughlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Laughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Laughlin. The network helps show where Mark Laughlin may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Laughlin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Laughlin Line = papers co-authored together Mark Laughlin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Inhibition of Entry of HIV-1 in Neural Cell Lines by Antibodies Against Galactosyl Ceramide Science ·Janet M. Harouse, Shama Bhat, Steven L. Spitalnik, Mark Laughlin, Kelly Stefano, Donald H. Silberberg, Francisco González‐Scarano	1991	445
2	Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults British Journal of Clinical Pharmacology ·Rachel Courtney, David Wexler, Elaine Radwanski, Josephine Lim, Mark Laughlin	2003	267
3	CD4-independent infection of human neural cells by human immunodeficiency virus type 1 Journal of Virology ·Janet M. Harouse, C Kunsch, Heather T. Hartle, Mark Laughlin, James A. Hoxie, Brian Wigdahl, Francisco González‐Scarano	1989	254
4	Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults Antimicrobial Agents and Chemotherapy ·Rachel Courtney, Sudhakar M. Pai, Mark Laughlin, Josephine Lim, Vijay Batra	2003	244
5	Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial The Lancet Neurology ·Gordon Wilcock, Sandra E. Black, Suzanne Hendrix, Kenton H. Zavitz, Edward A. Swabb, Mark Laughlin	2008	204
6	Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study European Journal of Pharmaceutical Sciences ·David Wexler, Ronan Courtney, William O. Richards, Christopher Banfield, Josephine Lim, Mark Laughlin	2004	167
7	Oral Bioavailability of Posaconazole in Fasted Healthy Subjects Clinical Pharmacokinetics ·Farkad Ezzet, David Wexler, Rachel Courtney, Gopal Krishna, Josephine Lim, Mark Laughlin	2005	151
8	Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men Antimicrobial Agents and Chemotherapy ·Rachel Courtney, Elaine Radwanski, Josephine Lim, Mark Laughlin	2004	113
9	Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals Alzheimer Disease & Associated Disorders ·Douglas Galasko, N. R. Graff-Radford, Susanne May, Suzanne Hendrix, Barbara A. Cottrell, Sarah A. Sagi, Gary Mather, Mark Laughlin, Kenton H. Zavitz, Edward A. Swabb, Todd E. Golde, Michael P. Murphy, Edward H. Koo	2007	94
10	Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease The Journal of Clinical Pharmacology ·Ronan Courtney, A Sansone, Winter J. Smith, T. Marbury, Paul Statkevich, M. Martinho, Mark Laughlin, Suzanne K. Swan	2005	94
11	Sodium Butyrate Treatment of Cells Latently Infected with HIV-1 Results in the Expression of Unspliced Viral RNA Virology ·Mark Laughlin, Steven L. Zeichner, Dennis L. Kolson, James C. Alwine, Thikkavarapu Seshamma, Roger J. Pomerantz, Francisco González‐Scarano	1993	61
12	Human choroid plexus cells can be latently infected with human immunodeficiency virus Annals of Neurology ·Janet M. Harouse, Zofia Wróblewska, Mark Laughlin, William F. Hickey, Barry S. Schonwetter, Francisco González‐Scarano	1989	50
13	Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation Journal of General Virology ·Dennis L. Kolson, Ronald G. Collman, Renee Hrin, John W. Balliet, Mark Laughlin, Kathleen A. McGann, Christine Debouck, Francisco González‐Scarano	1994	40
14	Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. Proceedings of the National Academy of Sciences ·H Zhang, Geethanjali Dornadula, P Alur, Mark Laughlin, Roger J. Pomerantz	1996	39
15	Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma Journal of Chromatography A ·Hong Kim, Pramila Kumari, Mark Laughlin, Mary Jane Hilbert, Stephen R. Indelicato, Josephine Lim, Chin‐Chung Lin, Amin A. Nomeir	2003	36
16	Maturation of Jejunum and Ileum in Rats Journal of Clinical Investigation ·M. K. Younoszai, R. S. Sapario, Mark Laughlin	1978	32
17	Sodium Butyrate Stimulation of HIV-1 Gene Expression Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Mark Laughlin, Gloria Y. Chang, Joseph W. Oakes, Fransisco Gonzalez-Scarano, Roger J. Pomerantz	1995	31
18	Entry of Human Immunodeficiency Virus-1 Into Glial Cells Proceeds via an Alternate, Efficient Pathway Journal of Leukocyte Biology ·Janet M. Harouse, Mark Laughlin, Charles H. Pletcher, Harvey M. Friedman, Francisco González‐Scarano	1991	19
19	O4–03–08: Efficacy and safety of MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, in Alzheimer's disease (AD): Results of a 12–month phase 2 trial and 1–year follow–on study Alzheimer s & Dementia ·Gordon Wilcock, Sandra E. Black, Judith Haworth, Suzanne Hendrix, Mark Laughlin, Kenton H. Zavitz, Daniel D. Christensen, Sheron Bass, Edward A. Swabb, (unknown)	2006	15
20	Estrogen blocks the protective action of melatonin in a behavioral model of ethanol-induced hangover in mice Physiology & Behavior ·Analía G. Karadayian, Mark Laughlin, Renato Cutrera	2012	13

About Mark Laughlin

Mark Laughlin is a scholar working on Infectious Diseases, Virology, Pharmacology, Physiology and Molecular Biology, having authored 33 papers that have together received 2.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (10 papers), Antifungal resistance and susceptibility (7 papers), Cholinesterase and Neurodegenerative Diseases (6 papers), Alzheimer's disease research and treatments (5 papers), HIV/AIDS Research and Interventions (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Computational Drug Discovery Methods (3 papers) and Pharmaceutical studies and practices (3 papers). The work is most often cited by research in Virology (731 citations), Infectious Diseases (1.2k citations), Epidemiology (934 citations), Pharmacology (397 citations) and Neurology (145 citations). Mark Laughlin has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Josephine Lim, Rachel Courtney, Francisco González‐Scarano, Janet M. Harouse, David Wexler, Elaine Radwanski, Steven L. Spitalnik, Donald H. Silberberg, Shama Bhat and Vijay Batra. Their work appears in journals such as Alzheimer s & Dementia, Clinical Pharmacology & Therapeutics, Antimicrobial Agents and Chemotherapy, Proceedings of the National Academy of Sciences and Annals of Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact